Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company that markets approximately 790 product lines in approximately 90 countries to approximately 4,800 customers. The company operates in the livestock sector, serving food animals including poultry, beef and dairy cattle, swine, aquaculture, and dogs, with a focus on regions where livestock production is consolidated in large commercial farms. The business is concentrated in the livestock sector, and the company is investing resources to further develop products for the companion animal sector. The company also manufactures and markets specific ingredients for use in the personal care, industrial chemical, and chemical catalyst industries.

The company competes in each of its markets with a number of large and small companies, some of which have greater financial, research and development, production, and other resources. Competition is based on brand recognition, product quality, price, and innovation. The company believes it is well positioned to grow its sales with its established network of sales, marketing, and distribution professionals in markets in North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East. The company's Class A common stock trades on the Nasdaq Stock Market under the symbol PAHC.

The company generates revenue by developing, manufacturing, and marketing a broad range of products for food animals, including antibacterials, anticoccidials, nutritional specialty products, vaccines, and vaccine adjuvants, as well as mineral nutrition products that fortify animal diets. Products are sold either directly to integrated poultry, cattle, and swine producers or through animal feed manufacturers, wholesalers, distributors, and veterinarians. The company manages its business in three segments: Animal Health, Mineral Nutrition, and Performance Products, each with its own dedicated management and sales team.

The Animal Health segment includes antibacterials, anticoccidials, nutritional specialty products, vaccines, and vaccine adjuvants, and also includes antibacterials and other processing aids used in the ethanol fermentation industry. For the year ended June 30, 2026, the Animal Health segment generated net sales of $1,162 million and Adjusted EBITDA of $304 million. The segment's net sales increased 21% from the prior year, and Adjusted EBITDA increased 37%.

The Mineral Nutrition segment provides mineral nutrition products that fortify animal diets and help maintain optimal health. For the year ended June 30, 2026, the Mineral Nutrition segment generated net sales of $282 million and Adjusted EBITDA of $22 million. The Performance Products segment sells performance products directly to customers in the personal care, industrial chemical, and chemical catalyst industries, and for the year ended June 30, 2026, it generated net sales of $74 million and Adjusted EBITDA of $8 million.

In April 2024, the company entered into a Purchase and Sale Agreement with Zoetis Inc. to acquire Zoetis's medicated feed additive portfolio, certain water-soluble products, and related assets. On October 31, 2024, the company completed the acquisition at a purchase price of approximately $297.5 million ($286.5 million, as adjusted, net of cash acquired). The product portfolio acquired generated $407.6 million in revenue in 2023 and is comprised of more than 37 product lines sold in approximately 80 countries. The acquisition also included six manufacturing sites, comprised of four in the U.S., one in Italy, and one in China. For the years ended June 30, 2026 and 2025, this product portfolio contributed $358.2 million and $208.2 million to overall net sales, respectively.

Total net sales for the year ended June 30, 2026 were $1,518 million, compared to $1,296 million in the prior year, an increase of 17%. Adjusted EBITDA for the year was $255 million, compared to $184 million in the prior year, an increase of 39%. Net sales by region for the year ended June 30, 2026 were: United States $877 million, Latin America and Canada $341 million, Europe, Middle East and Africa $188 million, and Asia Pacific $112 million.

A major growth vector is the integration and expansion of the acquired Zoetis medicated feed additive product portfolio, which generated $407.6 million in revenue in 2023 and contributed $358.2 million and $208.2 million to net sales in fiscal years 2026 and 2025, respectively. The acquisition included more than 37 product lines sold in approximately 80 countries and six manufacturing sites, and the company is focused on realizing the strategic benefits of this portfolio.

Another growth vector is the continued development of products for the companion animal sector, where the company is investing resources. The company is also focused on growing sales in regions where livestock production is consolidated in large commercial farms, leveraging its established network of sales, marketing, and distribution professionals across North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East.

The company's margin trajectory is reflected in the Adjusted EBITDA growth, which increased 39% to $255 million for the year ended June 30, 2026, from $184 million in the prior year. Segment Adjusted EBITDA for Animal Health increased 37% to $304 million, Mineral Nutrition increased 4% to $22 million, and Performance Products decreased 24% to $8 million. Corporate costs increased 12% to $78 million.

The company's operational outlook includes managing its manufacturing capacity and supply chain, as evidenced by the acquisition of six manufacturing sites from Zoetis. The company also continues to invest in technology infrastructure, as indicated by software and software development costs. The company's workforce strategy is not explicitly detailed in the filing.

The company's capital allocation priorities include managing its substantial level of indebtedness and related debt-service obligations. The company has a revolving credit facility and term loans under the 2024 Credit Agreement, and it has entered into interest rate swaps and foreign exchange options to manage market risk. The company also pays dividends, as evidenced by a subsequent event on July 29, 2026, related to dividends.

Structural headwinds include the potential for outbreaks of animal diseases, which could significantly reduce demand for products or availability of raw materials. Restrictions on the use of antibacterials in food-producing animals may change or become more prevalent, including limitations related to FDA Guidance 273 and similar initiatives. The company also faces risks from perceived adverse effects on human health linked to the consumption of food derived from animals that utilize its products.

Geographic and macro factors identified as constraints include the impact of armed conflicts in the Middle East and between Russia and Ukraine, which could affect operations and markets. The company also faces risks from currency fluctuations, changes in tax rates, and adverse U.S. and international economic market conditions. The company's dependence on Israeli and Brazilian operations is also a noted constraint.

Management's message emphasizes the company's position as a leading global diversified animal health and mineral nutrition company, with a focus on providing solutions to help livestock producers, farmers, veterinarians, and consumers maintain and enhance animal health. The strategic priorities emphasized include the successful integration of the acquired Zoetis medicated feed additive product portfolio, which generated $407.6 million in revenue in 2023 and contributed $358.2 million to net sales in fiscal year 2026, and the continued investment in the companion animal sector. Management also highlights the company's commitment to growing sales in key regions and managing its substantial indebtedness.

Total net sales for the year ended June 30, 2026 were $1,518 million, compared to $1,296 million in the prior year, an increase of 17%. Net income for the year was $222 million, compared to $279 million in the prior year, a decrease of 20%. Diluted earnings per share were $5.42 for the year ended June 30, 2026, compared to $6.82 in the prior year. Adjusted EBITDA was $255 million, compared to $184 million in the prior year, an increase of 39%. The company's cash position included cash and cash equivalents, and total debt included term loans and revolving credit facility borrowings under the 2024 Credit Agreement. The company's effective tax rate and other financial metrics are detailed in the financial statements. The Animal Health segment generated net sales of $1,162 million and Adjusted EBITDA of $304 million for the year ended June 30, 2026. The Mineral Nutrition segment generated net sales of $282 million and Adjusted EBITDA of $22 million. The Performance Products segment generated net sales of $74 million and Adjusted EBITDA of $8 million.

The company faces material risks from its substantial level of indebtedness, which requires significant debt-service obligations and is subject to covenants in its debt agreements. A material portion of sales and gross profits are generated by antibacterials and other related products, and restrictions on the use of antibacterials in food-producing animals, including FDA Guidance 273, could significantly reduce demand. The company is dependent on its Israeli and Brazilian operations, which are exposed to political and social instability, including armed conflicts in the Middle East. The company also faces risks from currency fluctuations, changes in tax rates, and adverse economic conditions. Additionally, the company's business could be negatively affected by outbreaks of animal diseases, which could reduce demand for products or availability of raw materials.